RealTime Dynamix™: Crohn’s Disease Q2 2017

Spherix Global Insights has just released the second quarter results of an independent survey regarding the evolving practice patterns in the management of Crohn’s disease (CD) in which US gastroenterologists (n=103) project significant gains for Janssen’s Stelara over the next six months.

Click the button below to view highlights from the cardiology and nephrology perspective reports:

RTD: Crohn’s Disease Q2 Spotlight

2017-07-05T18:33:44+00:00